<DOC>
	<DOC>NCT02878603</DOC>
	<brief_summary>The objective of this study is to evaluate long-term safety and efficacy of caplacizumab, to evaluate safety and efficacy of repeated use of caplacizumab and to characterize long term impact of TTP.</brief_summary>
	<brief_title>Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES)</brief_title>
	<detailed_description />
	<mesh_term>Purpura, Thrombocytopenic</mesh_term>
	<mesh_term>Purpura</mesh_term>
	<mesh_term>Purpura, Thrombotic Thrombocytopenic</mesh_term>
	<criteria>1. Completed the Final (28 day) FU visit in Study ALX0681C301. 2. Is â‰¥18 years of age at the time of signing the informed consent form (ICF). 3. Provided informed consent prior to initiation of any study specific activity/procedure. 4. Others as defined in the protocol 1. Not being able/willing to comply with the study protocol procedures. 2. Currently enrolled in a clinical study with another investigational drug or device. 3. Others as defined in the protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>